Khattar Jack A., the President and CEO of Supernus Pharmaceuticals, Inc., has reported a transaction involving 400,000 restricted stock units (RSUs). This filing, made on November 2, 2026, is significant as it aligns executive compensation with the company's performance, particularly in light of the upcoming merger with Indivior Pharmaceuticals, Inc.

Background

Supernus Pharmaceuticals, Inc., classified under the SIC code for Pharmaceutical Preparations, is a company based in Rockville, Maryland. The company focuses on developing and commercializing products for the treatment of central nervous system diseases. Recent filings indicate ongoing activity, with the latest being this Form 4, filed on November 2, 2026. Other recent filings include additional Form 4s from August and July of the same year.

What the Filing Says

The filing indicates that Khattar Jack A. acquired 400,000 RSUs on October 30, 2026. These RSUs will vest in installments, with 50% vesting upon the closing of the merger with Indivior Pharmaceuticals. The remaining units will vest in increments over the next three years, specifically 15% after one year, another 15% after two years, and 20% after three years.

Impact

This transaction may affect Supernus Pharmaceuticals' executive retention strategy, especially as the company prepares for its merger with Indivior. Aligning executive compensation with the success of the merger could be a strategic move to ensure leadership stability during a critical transition period.

What's Next

The filing does not say what happens next. However, the merger with Indivior Pharmaceuticals is anticipated to be a significant event for Supernus, and further updates regarding the merger and executive compensation may follow.